Article
Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
BMC cancer - 16 May 2013
Takada Mamoru, Higuchi Toru, Tozuka Katsunori, Takei Hiroyuki, Haruta Masayuki, Watanabe Junko, Kasai Fumio, Inoue Kenichi, Kurosumi Masafumi, Miyazaki Masaru, Sato-Otsubo Aiko, Ogawa Seishi, Kaneko Yasuhiko
Abstract excerpt
BACKGROUND: Chemotherapy with trastuzumab is widely used for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer, but a significant number of patients with the tumor fail to respond, or relapse. The mechanisms of recurrence and biomarkers that indicate the respon...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.